Abstract
Aspirin is known to have inter-individual variability in its pharmacodynamic response. Clinical investigators continue their empirical search for the optimum aspirin dose to safely prevent athero-thrombosis. Several patient populations have an accompanied accelerated platelet turnover that is associated with a time-dependent loss of aspirin efficacy. Increasing the dosing frequency has been shown to elicit better and more sustained platelet inhibition compared to a dose increase in these patient populations. This review explores the role of accelerated platelet turnover in aspirin pharmacodynamics and the benefits of multiple daily aspirin dosing.
Keywords: Antiplatelet, Aspirin, Essential Thrombocythemia, High On-Aspirin Platelet Reactivity, Platelet Turnover.
Related Journals
Current Drug Safety
Inflammation & Allergy - Drug Targets (Discontinued)
Recent Patents on Anti-Infective Drug Discovery
Current Drug Discovery Technologies
Current Drug Targets - Inflammation & Allergy
Current Bioactive Compounds
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Anti-Cancer Agents in Medicinal Chemistry
Current Drug Targets
Letters in Drug Design & Discovery
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development